Drug Trial Radar · NCT07195175
Study of MAR002 in Healthy Men
Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Aug 11, 2025
Primary completion
Jul 2026
Study completion Jul 2026
Sponsor
- Lead sponsor
- Marea TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men
Conditions
- Acromegaly
Interventions
MAR002Drug
subcutaneous injection
PlaceboDrug
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with TEAEs (treatment-emergent adverse events)Time frame: From first dose of study drug through final End of Study/Early Termination Visit. End of Study is Day 64 for Cohorts 1 and 2; End of Study is day 169 for Cohorts 3, 4, 5, and 6.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Marea Site
Tempe, Arizona · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.